Video

Addressing Frequent Cardiovascular Risk Factors in Visually Impaired Patients

Author(s):

CDC data suggest ophthalmic patients are significantly more likely to present with a heart disease-driving condition or habit. How could preventive care improve?

Research presented this week at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Sessions showed that patients with visual impairment are notably more likely to present with cardiovascular disease and risk factors for it than the general population.

In new data from US Centers for Disease Control and Prevention (CDC) investigators, presented by Elizabeth Lundeen, PhD, MPH, of the Division of Diabetes Translation at the CDC, patients with visual impairment who participated in a 2018 national health survey showed greater likelihood for more than a half-dozen risk factors associated with cardiovascular disease and major adverse cardiovascular events.

Among the most prevalent findings included a 46% greater likelihood of diabetes in visually-impaired persons versus the general population (associated prevalence ratio [aPR], 1.46; 95% CI, 1.32 - 1.63), and 36% greater likelihood of smoking status (aPR, 1.36; 95% CI, 1.24 - 1.48).

In an interview with HCPLive during ARVO 2021, Lundeen discussed how the observed risk factors—which additionally included obesity and hypertension, among others—closely overlap between cardiovascular disease and age-related macular degeneration (AMD), the leading cause of blindness in the US.

“There’s just a strong correlation between cardiovascular health and vision health,” she explained.

Lundeen also discussed how the findings, which only cement the linkage between health- and lifestlye-related cardiovascular risk factors and worsened vision health, could provide guidance for experts to be “creative” with their chronic disease-preventive solutions.

“I think there are opportunities to better integrate vision screening and attention to vision health within routine clinical care—whether it’s from a general practitioner, an endocrinologist, a cardiologist,” she said. “As well, there are opportunities to integrate chronic disease prevention into rehabilitative vision services.”

Related Videos
Davide Matino, MD, MSc: Bringing Marstacimab Treatment to Hemophilia A and B
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Highlighting the Danger of SCI Progression during iTTP Remission, with Shruti Chaturvedi, MBSS, MS
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.